The heterogeneity of the aging process and lack of consensus on the biomarkers of aging make it difficult to pinpoint universal targets that can be applied to the wider population. With increasing progression in the longevity and aging industry, these challenges need to be addressed to gain a more comprehensive understanding of the intricate mechanisms underlying the aging process.

Join this workshop to discuss:

• Using genomics to drive druggable target identification and validation
• Assessing molecular and cellular factors that contribute to aging to identify potential
  targets for intervention
• Navigating recent progression in defining reliable biomarkers to accurately
  represent the aging process
• Focussing on organ-specific aging clocks rather than an individual’s biological clock
  to guide intervention
• Adapting therapeutic strategies to address the evolving nature of aging